All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Lipidized prolactin-releasing peptide improved glucose tolerance in metabolic syndrome: Koletsky and spontaneously hypertensive rat study

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388963%3A_____%2F18%3A00489671" target="_blank" >RIV/61388963:_____/18:00489671 - isvavai.cz</a>

  • Alternative codes found

    RIV/67985823:_____/18:00489814 RIV/00216208:11110/18:10375110 RIV/00023761:_____/18:N0000020 RIV/00023001:_____/18:00076566 RIV/00064165:_____/18:10375110

  • Result on the web

    <a href="https://www.nature.com/articles/s41387-017-0015-8" target="_blank" >https://www.nature.com/articles/s41387-017-0015-8</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1038/s41387-017-0015-8" target="_blank" >10.1038/s41387-017-0015-8</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Lipidized prolactin-releasing peptide improved glucose tolerance in metabolic syndrome: Koletsky and spontaneously hypertensive rat study

  • Original language description

    Background/Objectives: Prolactin-releasing peptide (PrRP) has a potential to decrease food intake and ameliorate obesity, but is ineffective after peripheral administration. We have previously shown that our novel lipidized analogs PrRP enhances its stability in the circulation and enables its central effect after peripheral application. The purpose of this study was to explore if sub-chronic administration of novel PrRP analog palmitoylated in position 11 (palm(11)-PrRP31) to Koletsky-spontaneously hypertensive obese rats (SHROB) could lower body weight and glucose intolerance as well as other metabolic parameters. Subjects/Methods: The SHROB rats (n = 16) were used for this study and age-matched hypertensive lean SHR littermates (n = 16) served as controls. Palm(11) -PrRP31 was administered intraperitoneally to SHR and SHROB (n = 8) at a dose of 5mg/kg once-daily for 3 weeks. During the dosing period food intake and body weight were monitored. At the end of the experiment the oral glucose tolerance test was performed, plasma and tissue samples were collected. Thereafter, arterial blood pressure was measured. Results: At the end of the experiment, vehicle-treated SHROB rats showed typical metabolic syndrome parameters, including obesity, glucose intolerance, dyslipidemia, and hypertension. Peripheral treatment with palm(11)-PrRP31 progressively decreased the body weight of SHR rats but not SHROB rats, though glucose tolerance was markedly improved in both strains. Moreover, in SHROB palm(11)-PrRP31 ameliorated the HOMA index, insulin/glucagon ratio, and increased insulin receptor substrate 1 and 2 expression in fat and insulin signaling in the hypothalamus, while it had no effect on blood pressure. Conclusions: We demonstrated that our new lipidized PrRP analog is capable of improving glucose tolerance in obese SHROB rats after peripheral application, suggesting that its effect on glucose metabolism is independent of leptin signaling and body weight lowering. These data suggest that this analog has the potential to be a compound with both anti-obesity and glucose-lowering properties.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30105 - Physiology (including cytology)

Result continuities

  • Project

    <a href="/en/project/GA15-08679S" target="_blank" >GA15-08679S: The possible role of stable analogs of prolactin-releasing peptide in experimental models of obesity and hypertension</a><br>

  • Continuities

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Others

  • Publication year

    2018

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Nutrition & Diabetes

  • ISSN

    2044-4052

  • e-ISSN

  • Volume of the periodical

    8

  • Issue of the periodical within the volume

    Jan 16

  • Country of publishing house

    GB - UNITED KINGDOM

  • Number of pages

    9

  • Pages from-to

  • UT code for WoS article

    000425644700001

  • EID of the result in the Scopus database

    2-s2.0-85040834352